Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Humans Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

NCT02304185
View directory record Official record
Conditions
Healthy
Interventions
gp140, 50 mcg, gp140, 50 mcg + Adjuvant, gp140, 250 mcg, gp140, 250 mcg + Adjuvant, Placebo
Biological · Drug
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

NCT02509117
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose, Placebo multiple dose, PF-06751979 multiple dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 3, 2026, 11:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Test of QLS Device to Detect Early Cataracts

NCT00001617
View directory record Official record
Conditions
Cataract, Healthy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 11:50 PM EDT
Recruiting No phase listed Observational

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

NCT05181826
View directory record Official record
Conditions
Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Interventions
Multi-analyte Blood Test
Diagnostic Test
Lead sponsor
Helio Genomics
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Timeline
2019 – 2028
U.S. locations
7
States / cities
Redondo Beach, California • Coon Rapids, Minnesota • Fridley, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 3, 2026, 11:50 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants

NCT07602335
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Placebo, MCAM
Other · Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

NCT05169671
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ATH-1020, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

NCT05393271
View directory record Official record
Conditions
HIV Infections
Interventions
VH4011499, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

NCT00873912
View directory record Official record
Conditions
Healthy
Interventions
Monovalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Sep 3, 2026, 11:50 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

NCT05703607
View directory record Official record
Conditions
Shingles, Herpes Zoster Infection, Human
Interventions
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
35
States / cities
Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

NCT01005407
View directory record Official record
Conditions
Healthy
Interventions
HEPLISAV and/or Placebo, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years to 70 Years
Enrollment
2,452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
29
States / cities
Huntsville, Alabama • San Diego, California • Santa Ana, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

NCT01411800
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
250 mg capsule, 250 mg tablets
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H9 Priming Study in Healthy Adults

NCT00617331
View directory record Official record
Conditions
Influenza
Interventions
Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

NCT00120081
View directory record Official record
Conditions
Hookworm Infection
Interventions
Na-ASP-2/Alhydrogel Hookworm Vaccine, Saline placebo
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

NCT05760937
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986447, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)

NCT00380237
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus

NCT01044095
View directory record Official record
Conditions
Influenza
Interventions
FluMist® live, attenuated, intranasal seasonal influenza vaccine, Fluzone® inactivated influenza virus vaccine
Biological
Lead sponsor
Armed Forces Research Institute of Medical Sciences, Thailand
Government
Eligibility
18 Years to 49 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

NCT02921997
View directory record Official record
Conditions
Avian Influenza, H1N1 Influenza, Influenza
Interventions
AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 3, 2026, 11:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ultrasound of the Spleen Utilizing Low-energy (Diagnostic Level) Insonification.

NCT06934096
View directory record Official record
Conditions
Hemostasis, Blood Biomarkers, Ultrasound
Interventions
Ultrasound Pulsed Doppler Imaging System
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

NCT03210961
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

NCT00546585
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H7N7 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

NCT00328107
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccine, recombinant Hemagglutinin
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Sep 3, 2026, 11:50 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing and Improving Quantitative Magnetic Resonance Imaging Metrics in Human Subjects

NCT05604534
View directory record Official record
Conditions
Normal Physiology
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2041
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dolutegravir Renal Impairment Study

NCT01353716
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 3, 2026, 11:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

NCT02914184
View directory record Official record
Conditions
Infections, Rotavirus, Rotavirus Vaccines
Interventions
HRV PCV-free liquid vaccine, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Anaheim, California • Paramount, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 3, 2026, 11:50 PM EDT